Exalenz Bioscience Ltd.

Company Profile

Exalenz Bioscience Ltd. develops and commercializes advanced systems that extract vital information for diagnostics from subtle changes in the patient`s exhaled breath. Our proprietary core technology enables medical specialists to identify and manage specific digestive and liver conditions with unprecedented ease, patient comfort, and clinical precision.

The company`s flagship product, the BreathID System, answers a long-standing need for fast and accurate assessment and monitoring of functional diseases of the liver and gastrointestinal tract. It measures parts-per-million changes in the molecular 13C/12C ratio of the patient`s exhaled breath, continuously, automatically, and in real time. Furthermore, the BreathID System is mobile, user-friendly, and can be operated in any clinical setting.

The design of sophisticated diagnostic systems that are simple to operate is a hallmark of Exalenz. The company conducts ongoing research in collaboration with leading clinical and industrial partners in the U.S., Europe, Asia, and Israel.

The Exalenz Vision

As our name implies, we define "excellence" as successfully meeting the patients` needs for a better quality of life. Our technology furthers this goal by providing both medical professionals and patients with advanced solutions, vital for diagnostic medicine.

2010 Exalenz Bioscience Ltd. All Rights Reserved
Developed by Moonsite

Disclaimer: In the USA, The BreathID System is intended for use in the qualitative detection of H. pylori. It has an approved 510(K) and an approved NDA for the 13 C-urea Tablet and Citrica Powder . Other applications are limited by Federal (of United States) Law to Investigational Use only. In Europe: The BreathID System has a CE approval for assessing Helicobacter pylori, Liver Function, and Gastric Emptying Rate.